341 related articles for article (PubMed ID: 26966785)
21. [Graves' ophthalmopathy].
Eckstein A; Esser J
Internist (Berl); 2010 May; 51(5):584, 586-8, 590-2, passim. PubMed ID: 20383481
[TBL] [Abstract][Full Text] [Related]
22. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy.
Elbers L; Mourits M; Wiersinga W
Thyroid; 2011 Mar; 21(3):279-83. PubMed ID: 21190446
[TBL] [Abstract][Full Text] [Related]
23. Perspectives in pharmacological management of Graves' hyperthyroidism and orbitopathy.
Bartalena L; Lai A; Tanda ML
Expert Rev Clin Immunol; 2008 May; 4(3):321-9. PubMed ID: 20476922
[TBL] [Abstract][Full Text] [Related]
24. [Graves' ophthalmopathy].
Eckstein A; Dekowski D; Führer-Sakel D; Berchner-Pfannschmidt U; Esser J
Ophthalmologe; 2016 Apr; 113(4):349-64; quiz 465-6. PubMed ID: 27059986
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
[TBL] [Abstract][Full Text] [Related]
26. Selenium and the course of mild Graves' orbitopathy.
Marcocci C; Kahaly GJ; Krassas GE; Bartalena L; Prummel M; Stahl M; Altea MA; Nardi M; Pitz S; Boboridis K; Sivelli P; von Arx G; Mourits MP; Baldeschi L; Bencivelli W; Wiersinga W;
N Engl J Med; 2011 May; 364(20):1920-31. PubMed ID: 21591944
[TBL] [Abstract][Full Text] [Related]
27. [Novel treatment opportunities in Graves' orbitopathy].
Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE
Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914
[TBL] [Abstract][Full Text] [Related]
28. A questionnaire survey on the management of Graves' orbitopathy in Europe.
; Perros P; Baldeschi L; Boboridis K; Dickinson AJ; Hullo A; Kahaly GJ; Kendall-Taylor P; Krassas GE; Lane CM; Lazarus JH; Marcocci C; Marino M; Mourits MP; Nardi M; Orgiazzi J; Pinchera A; Pitz S; Prummel MF; Wiersinga WM
Eur J Endocrinol; 2006 Aug; 155(2):207-11. PubMed ID: 16868132
[TBL] [Abstract][Full Text] [Related]
29. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
30. [Perioperative treatment for the urgent orbital decompression surgery in a 30-weeks pregnant woman with Graves' orbitopathy].
Guerrero-Domínguez R; López-Herrera-Rodríguez D; Domínguez-Blanco A; Medina-de Moya I; Sánchez-Carrillo F
Rev Esp Anestesiol Reanim; 2014; 61(6):342-5. PubMed ID: 23835254
[TBL] [Abstract][Full Text] [Related]
31. [Management of patient with Gaves' orbitopathy].
Di Fiore A; Paone L; Rendina R; D'Armiento E; Coccaro C; Alessandrini S; Marenco M; Ulisse S
Clin Ter; 2012 Nov; 163(6):e463-74. PubMed ID: 23306763
[TBL] [Abstract][Full Text] [Related]
32. [Management of Graves' orbitopathy: evidence-based recommendations].
Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
[TBL] [Abstract][Full Text] [Related]
33. Surgical treatment of globe subluxation in the active phase of the myogenic type of Graves orbitopathy: case reports.
Eing F; Cruz AA
Arq Bras Oftalmol; 2012; 75(2):131-3. PubMed ID: 22760806
[TBL] [Abstract][Full Text] [Related]
34. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
[TBL] [Abstract][Full Text] [Related]
35. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
36. The relationship between quality of life, cognition, and thyroid status in Graves' disease.
Riguetto CM; Neto AM; Tambascia MA; Zantut-Wittmann DE
Endocrine; 2019 Jan; 63(1):87-93. PubMed ID: 30173328
[TBL] [Abstract][Full Text] [Related]
37. Commentary: rituximab, adalimumab, etanercept, tocilizumab--are biologics the future for Graves' orbitopathy?
Bartalena L
Ophthalmic Plast Reconstr Surg; 2014; 30(5):420-3. PubMed ID: 25025391
[TBL] [Abstract][Full Text] [Related]
38. Efficacy Profile and Safety of Very Low-Dose Rituximab in Patients with Graves' Orbitopathy.
Vannucchi G; Campi I; Covelli D; Currò N; Lazzaroni E; Palomba A; Soranna D; Zambon A; Fugazzola L; Muller I; Guastella C; Salvi M
Thyroid; 2021 May; 31(5):821-828. PubMed ID: 33234032
[No Abstract] [Full Text] [Related]
39. Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with Europe.
Ramos HE; Diehl LA; Camacho CP; Perros P; Graf H;
Clin Endocrinol (Oxf); 2008 Dec; 69(6):951-6. PubMed ID: 18462263
[TBL] [Abstract][Full Text] [Related]
40. [Intraorbital pressure measured before, during, and after surgical decompression in Graves' orbitopathy].
Berthout A; Vignal C; Jacomet PV; Galatoire O; Morax S
J Fr Ophtalmol; 2010 Nov; 33(9):623-9. PubMed ID: 21047700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
